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De novo phosphatidylcholine (PC) synthesis via CTP:phosphocholine cytidylyltransferase-α 
(CTα) is required for very-low-density lipoprotein secretion. To determine the precise role of de 
novo PC synthesis in intestinal lipid metabolism, we deleted CTα exclusively in the intestinal 
epithelium of mice (CTαIKO mice). When fed a chow diet, CTαIKO mice showed normal fat 
absorption despite a ~30% decrease in intestinal PC concentrations relative to control mice, 
suggesting that biliary PC can fully support chylomicron secretion under these conditions. 
However, when fed a high-fat diet, CTαIKO mice showed impaired passage of fatty acids and 
cholesterol from the intestinal lumen into enterocytes. Impaired intestinal lipid uptake in CTαIKO 
mice was associated with lower plasma triglyceride concentrations, higher plasma Glucagon-like 
Peptide 1 and Peptide YY, and disruption of intestinal membrane lipid transporters after a high 
fat meal relative to control mice. Unexpectedly, biliary bile acid and PC secretion was enhanced 
in CTαIKO mice due to a shift in expression of bile-acid transporters to the proximal intestine, 
indicative of accelerated enterohepatic cycling. These data show that intestinal de novo PC 
synthesis is required for dietary lipid absorption during high-fat feeding and that the re-acylation 
of biliary lyso-PC cannot compensate for loss of CTα under these conditions. 
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Phospholipids form the matrix of biological membranes, provide precursors for a variety 
of signaling molecules, and allow assembly and secretion of lipoproteins (1). 
Phosphatidylcholine (PC) is the primary phospholipid in eukaryotic cells (1). The amphitropic 
enzyme CTP: phosphocholine cytidylyltransferase (CT) regulates de novo PC synthesis in 
response to changes in membrane lipid composition in all nucleated mammalian cells (2). Global 
deletion of CTα (encoded by Pcyt1a) is embryonic lethal in mice, reflecting the essential role of 
membrane biogenesis during development (3). Mice lacking CTα in the liver have impaired 
very-low-density lipoprotein (VLDL) secretion and accumulate neutral lipids in hepatocytes (4) 
despite the presence of a second route for hepatic PC synthesis via the methylation of 
phosphatidylethanolamine (PE) by phosphatidylethanolamine-N-methyltransferase (PEMT). 
Similarly, CTα cannot compensate for the loss of PEMT in generating PC for VLDL assembly 
(5). 
Intestinal PC can be derived from the diet, bile, circulating lipoproteins, and from local 
de novo synthesis. Dietary and biliary PC is hydrolyzed in the intestinal lumen by phospholipase 
A2 to lyso-PC and fatty acids before being absorbed into enterocytes, delivered to the 
endoplasmic reticulum, and re-acylated into PC by lyso-PC acyltransferase (Lpcat) enzymes (6, 
7). Mice lacking hepatic Abcb4, which is required for PC secretion into bile, have normal 
passage of fatty acids from the intestinal lumen into enterocytes but have impaired chylomicron 
assembly and secretion, highlighting the importance of biliary PC for chylomicron output (8). 
Furthermore, loss of intestinal Lpcat3, which incorporates polyunsaturated fatty acids into PC, 
impairs dietary lipid absorption despite maintenance of total intestinal PC mass (9, 10). 
Conversely, increasing the delivery of PC to the intestinal lumen promotes chylomicron 











secretion (11). Therefore, while the re-acylation of lyso-PC derived from the intestinal lumen is 
important for chylomicron production, the precise contribution that intestinal de novo PC 
synthesis makes to this process is unknown. 
In the present study we hypothesized that loss of intestinal CTα activity would cause TG 
accumulation in enterocytes due to insufficient supply of PC for chylomicron assembly. 
However, we unexpectedly found that loss of intestinal de novo PC synthesis impairs passage of 
fatty acids from the intestinal lumen into enterocytes in the setting of a high fat diet (HFD), but 
not a chow diet. Fat malabsorption is linked to the repression of genes involved in fatty acid 
uptake, enhanced postprandial enteroendocrine hormone secretion, and reduced adiposity. 
Furthermore, we show that loss of intestinal CTα promotes biliary bile acid and lipid secretion 
by accelerating enterohepatic bile acid cycling. Our data provide evidence of a specific 
requirement for intestinal de novo PC synthesis in the maintenance of intestinal metabolic 
functions and show that the re-acylation of lyso-PC from extra-intestinal sources is insufficient 
to maintain metabolic function during HFD feeding.   
 
MATERIALS AND METHODS 
Generation of mice with intestine-specific deletion of Pcyt1a 
Mice carrying a floxed Pcyt1a locus (Pcyt1aLoxP/LoxP) on a C57BL/6J background were crossed 
with mice expressing a tamoxifen-inducible Cre-recombinase transgene under the control of a 
villin promoter (villin-CreERT2) (12) to generate Pcyt1aLoxP/WT;villin-CreERT2 mice (with the 
capacity to induce a heterozygous deletion of intestinal CTα after tamoxifen treatment). 
Subsequent cross-breeding of Pcyt1aLoxP/WT;villin-CreERT2 mice resulted in the generation of 











Pcyt1aLoxP/LoxP;villin-CreERT2 mice (with the capacity to induce a homozygous deletion of 
intestinal CTα after tamoxifen treatment). Genomic DNA was extracted from tail biopsies with a 
DNeasy Blood and Tissue Kit (Qiagen, UK). PCR products were identified on a 3% agarose gel 
(floxed Pcyt1a band) or a 1.5% agarose gel (Villin Cre-inducible band). Cre was induced in 8-
12-week-old male or female mice by intraperitoneal injection of tamoxifen (1mg/day in 
sunflower oil for 5 days; Sigma, St. Louis, MO), while tamoxifen-treated Pcyt1aLoxP/LoxP mice 
were used as controls. Mice were fed a chow diet (5001, Lab Diet, St. Louis, MO) or a semi-
purified HFD containing 40% kilocalories as fat (Supplementary Table S1). Mice were housed in 
a temperature-controlled room with 12-h light/dark cycle and free access to food and water. 
Samples were collected after a 10-h fast or after overnight fasting followed by 2-h re-feeding, 
unless otherwise stated. Small intestines were excised, flushed with phosphate buffered saline 
(PBS) containing protease inhibitor cocktail (Sigma, St. Louis, MO), and kept on ice. The small 
intestine was divided into 3 portions of length ratio 1:3:2 (corresponding to duodenum: jejunum: 
ileum) before jejunum sections were fixed in 10% neutral-buffered formalin for histology. 
Epithelial cells were collected in liquid nitrogen after segments were opened longitudinally. The 
University of Alberta’s Institutional Animal Care Committee approved all animal procedures, 
which were in accordance with guidelines of the Canadian Council on Animal Care. 
Microscopy  
Formalin-fixed, paraffin-embedded tissue slices (5µm thick) were stained with hematoxylin and 
eosin (H&E) and visualized with a light microscope. For electron microscopy, 2cm jejunal rings 
were fixed with 2% paraformaldehyde and 2.5% glutaraldehyde in 0.1M phosphate buffer (pH 
7.2). Sections were cryo-sectioned with an ultramicrotome (Ultracut E, Reichert-Jung) equipped 











with an FC4D attachment, and images were obtained using a Philips 410 transmission electron 
microscope.  
mRNA isolation and quantification by PCR 
 Total RNA was isolated from intestinal scrapings or liver using Trizol (Invitrogen, CA, USA). 
RNA was reversed-transcribed using Superscript II (Invitrogen, CA, USA). Quantitative PCR 
was run on an Applied Biosystems StepOne Plus for 40 cycles using a Power SYBR Green PCR 
Master Mix (Applied Biosystems, MA, USA), in triplicate. Relative mRNA expression was 
normalized to cyclophilin. Quantitation was performed using the standard curves method. Primer 
sequences are listed in Supplementary Table S2.  
Fatty acid absorption  
Intestinal fatty acid absorption was quantified as described previously (13), with modifications. 
Briefly, male control and CTαIKO mice were fasted for 4 h before receiving an oral gavage of 
150µL of olive oil containing 5µCi [3H]-labelled triolein. Blood was collected at 30, 60, 90 and 
120 mins post-gavage. At 120 mins post-gavage, the small intestine was excised, flushed with 
40ml PBS containing 0.5mM sodium taurocholate and cut into 2cm segments. Segments were 
dissolved in 1N NaOH for 3 days at 60  ֯ C. Plasma and tissue [3H]-label was measured by liquid 
scintillation counting (Beckman Coulter Inc, CA). For poloxamer studies, mice were fasted for 
10 h before receiving an intraperitoneal injection of Poloxamer-407 (1g/kg; Sigma, MO, USA) 
and an oral gavage of 150µL olive oil. Blood was collected before, and every hour for 4 h after 
the oil challenge. Plasma TG concentrations were assessed using a commercially available kit 
(Sekisui Diagnostics, MA). To visualize intestinal lipid droplets after a fat challenge, 4-h fasted 
female mice were gavaged (7.5µL/g mouse) with olive oil containing 20% Bodipy 500/510 C1, 











C12 (D3823, Invitrogen, CA, USA). Sections of the proximal small intestine were embedded in 
optimum cutting temperature (OCT) and sliced on cryostat at -20 degrees Celsius. Slides were 
mounted with Prolong Diamond Antifade Mountant containing DAPI (P36962, Invitrogen, CA, 
USA) before images were obtained with a fluorescence microscope (Olympus, Markham, ON) 
equipped with Suveyor and ImagePro Plus software. 
Cholesterol absorption 
Individually-housed male control and CTαIKO mice received an oral dose of [3H]-cholesterol (2 
µCi) with 6mg unlabeled cholesterol in 150µL of olive oil, and an intravenous injection of [14C]-
cholesterol (1µCi) mixed in Intralipid®. Blood and feces was collected at 24, 48 and 72 h after 
cholesterol administration. Blood was centrifuged at 3000g for 10 minutes and plasma was 
collected. Plasma [3H]-label and [14C]-label was measured by liquid scintillation counting 
(Beckman Coulter Inc, CA). The [3H]-label and [14C]-label in fecal neutral sterol and fecal bile 
salt (aqueous) fractions were measured by liquid scintillation counting (Beckman Coulter Inc, 
CA) after separation of the fractions by the method of Folch (14).   
Gallbladder cannulations and bile measurements 
For gallbladder cannulations, male mice were anesthetized by intraperitoneal injection of 
ketamine (100mg/kg)/ xylazine (10mg/kg). Gallbladders were cannulated with silastic tubing 
(Dow Corning, MI; internal diameter 0.5mm) after ligation of the common bile duct beside the 
duodenum. Mice were placed in a humidified incubator and bile was collected for 30 mins in 
pre-weighed vials. Bile acid species composition (including taurohyodeoxycholic acid 
(THDCA), tauro-β-muricholic acid (TB-MCA), tauro-α-muricholic acid (TA-MCA), β-
muricholic acid (β-MCA), taurodeoxycholic acid (TDCA), taurochenodeoxycholic acid 











(TCDCA), taurocholic acid (TCA), tauroursodeoxycholic acid (TUDCA) and cholic acid (CA)) 
was determined by liquid chromatography tandem mass spectrometry (LC-MS/MS) as described 
previously (15). The hydrophobicity of bile acids was determined according to the method of 
Heuman (16). Biliary lipids were extracted by the method of Folch (14). Biliary phospholipid 
concentrations were assessed by phosphorous assay, as described previously (17). Biliary 
cholesterol concentrations were measured with a commercially available kit (WAKO Chemicals, 
USA). Biliary secretion rates were calculated by multiplying biliary bile acid, phospholipid, or 
cholesterol concentrations by bile flow (µL/min). Bile acid concentrations in feces and plasma 
were determined by enzymatic fluorometric assay (18).  
Plasma, tissue, and fecal lipid analysis  
Plasma TG (Sekisui Diagnostics, MA, USA), cholesterol (Wako Chemicals, USA) and non-
esterified fatty acids (Wako Chemicals, USA) were measured with commercially available kits. 
Lipoprotein fractions were separated from pooled plasma samples (5 mice per group) by size 
exclusion fast protein liquid chromatography (FPLC) before measuring TG and cholesterol 
concentrations by commercially-available kits (Lipidomics Core Facility, University of Alberta). 
Total protein concentrations of tissue homogenates were determined by bicinchoninic acid assay 
before tissue lipids were extracted from homogenates (1mg/ml) by the method of Folch (14).  PC 
and phosphatidylethanolamine (PE) were separated by thin layer chromatography using the 
solvent system chloroform:methanol:acetic acid:water (50:30:8:4). Bands were visualized after 
exposure to iodine and measured by phosphorous assay, as described previously (17). Intestinal 
TG concentrations were measured using a commercially available kit (Sekisui Diagnostics, MA, 
USA). The relative abundance of PC species in jejunal epithelial cells was measured by mass 
spectrometry at The Metabolomics Innovation Centre, University of Alberta. To analyze the fatty 











acid composition of intestinal PC, lipids were extracted from intestinal scrapings and separated 
by thin-layer chromatography as described above. PC bands were recovered from the plates and 
converted to fatty acid methyl esters by incubation with 2 ml of hexane (Sigma Aldrich, 293253) 
and 1.5ml boron trifluoride (Sigma-Aldrich, B1252) in methanol for 1 h at 110 °C. Fatty acid 
methyl esters were then analyzed by gas-liquid chromatography (results are shown as the 
percentage of total fatty acids measured). Intestinal non-esterified cholesterol and cholesterol 
esters were measured by gas-liquid chromatography with flame ionization detection (GC-FID) 
after derivatization with bis(trimethylsilyl)trifluoroacetamide and adjustment of peaks with the 
internal standard tridecanoin, as described previously (19). Fecal samples (50mg) were dried and 
ground to a powder before extraction of lipids by the method of Folch (14). Non-esterified fatty 
acid and cholesterol concentrations in feces of female mice collected over 72 h were determined 
with commercially available kits (Wako Chemicals, USA).  
Measurement of intestinal CT activity  
Intestinal CTα activity was determined by measuring the conversion of [3H]phosphocholine into 
[3H]CDP-choline, as described previously (4).  
Plasma metabolite measurements  
Blood glucose was measured from the tail vein with a glucometer (Accu-chek, Roche, 
Switzerland) after a 10-h fast, after 2 h re-feeding or after 2 h re-feeding followed by an oral 
gavage of glucose (2mg/g body weight). Blood was collected by cardiac puncture in tubes 
containing EDTA, dipeptidyl peptidase 4 inhibitor (EMD Millipore, MA, USA) and Complete® 
general protease inhibitor (Sigma, MO, USA) before being centrifuged at 3000g for 10 minutes 
to obtain plasma. Plasma insulin (Meso Scale Diagnostics, MD, USA), leptin (Meso Scale 











Diagnostics, MD, USA), active GLP-1 (EMD Millipore, MA, USA), PYY (Crystal Chem IL, 
USA), and FGF21 (Abcam, Cambridge, UK) were measured by enzyme-linked immunosorbent 
assay, according to the manufacturer’s instructions. Plasma (4µL) was resolved on a sodium 
dodecyl sulfate polyacrylamide gel (5% gel for ApoB and 10% for ApoA1). Proteins were 
transferred to a to a polyvinylidene difluoride membrane and probed with either anti-
Apolipoprotein B (dilution 1:7500, AB742; Chemicon, MA, USA) or Anti-Apolipoprotein A1 
(dilution 1:2000; K23001R, BioDesign/Meridian). ApoB and ApoA1 were run on separate gels. 
Immunoreactive proteins were detected with Enhanced ChemiLuminescence (ECL; Amersham, 
GE Healthcare, UK), and blots were imaged with a ChemiDoc MP Imager, (Bio-rad 
Laboratories, CA, USA).   
Statistics 
Data are expressed as mean ± standard error of the mean using Graphpad Prism 7 (GraphPad 
Software, La Jolla, CA); p < 0.05 was considered statistically significant. Student’s t-test was 
used to compare two independent groups. A one-way ANOVA was used when comparing 3 
groups with one experimental outcome. A two-way ANOVA with Bonferroni post-test was used 
to determine the effect of genotype and time on an experimental outcome. 
 
RESULTS 
Intestinal PC concentrations are reduced in CTα IKO mice fed a chow diet, but fat 
absorption capacity is unaltered. 
Induction of Cre recombinase with tamoxifen in Pcyt1aLoxP/LoxP;villin-CreERT2 mice (herein 
referred to as CTαIKO mice) reduced Pcyt1a mRNA abundance and CTα enzyme activity in the 











jejunum and ileum by >90% compared to tamoxifen-treated Pcyt1aLoxP/LoxP control mice (Fig. 1A 
and 1B and supplementary Fig. S1A). Pcyt1a mRNA remained repressed in the intestines of 
CTαIKO mice for at least 50 days following Cre induction (supplementary Fig. S1B). 
Characterization of mice with a heterozygous deletion of intestinal CTα fed either a chow diet 
(supplementary Fig. S1D-S1H) or a HFD (supplementary Fig. S1I-S1M) revealed no differences 
in body weight, blood glucose, plasma lipids, or fat absorption after an oral lipid bolus despite a 
~50% decrease in intestinal Pcyt1a mRNA abundance compared to control mice (supplementary 
Fig. S1C).   
Loss of intestinal CTα did not impact survival of the mice fed the chow diet, and body mass 
of CTαIKO mice was comparable to that of controls after 6 weeks (Fig. 1C). Furthermore, 
histological examination of H&E-stained jejunum sections at 6 weeks after Cre induction 
revealed no overt morphological abnormalities in CTαIKO intestines compared to control 
intestines (Fig. 1D). This finding suggests that intestinal CTα activity is not required for 
maintenance of epithelial cell turnover in adult mice. PC concentrations were lower in the 
jejunum and ileum of CTαIKO mice compared to controls after an oil challenge (Fig. 1E). 
Furthermore, PE concentrations were higher in the jejunum of CTαIKO mice (Fig. 1F). This 
resulted in a relatively large decrease in the molar ratio of PC-to-PE in the intestines of CTαIKO 
mice (Fig. 1G). Fasting plasma cholesterol concentrations (Fig. 1H) were significantly lower in 
CTαIKO mice fed the chow diet, while fasting plasma TG (Fig. 1I), insulin and blood glucose 
concentrations (not shown) were unchanged compared to control mice.  
Unexpectedly, despite the absence of intestinal CTα activity and a dramatic decrease in the 
PC/PE ratio of intestinal membranes, TG appearance in plasma was comparable between CTαIKO 
mice and control mice after an oral bolus of olive oil (Fig. 1J). This finding suggests that, in 











contrast to the liver where ‘new’ PC synthesis is required for VLDL secretion (4), intestinal de 
novo PC synthesis is dispensable for chylomicron secretion in the setting of a low-fat diet. These 
results also suggest that PC supplied to the intestine in bile is sufficient for chylomicron 
formation and secretion under these conditions.  
HFD feeding initially induces rapid weight loss, while chronic HFD feeding reduces weight 
gain, in CTαIKO mice  
We hypothesized that feeding mice a HFD would increase demand for lipid droplet and 
chylomicron PC and therefore induce more pronounced changes to the intestinal epithelium of 
CTαIKO mice. Analysis of 3 independent experiments showed that 26% of CTαIKO mice (5 of 19) 
lost ~25% body weight and displayed steatorrhea between days 4 and 5 following initiation of 
the HFD, forcing termination of these mice under protocol requirements (Fig. 2A). Interestingly, 
the remaining 74% of CTαIKO mice experienced only modest weight loss but had significantly 
less visceral fat mass and lower plasma leptin concentrations than did control mice on day 6 
following initiation of the HFD (Fig. 2B and 2C). Weight loss in CTαIKO mice coincided with 
reduced food intake (2.76 g ± 0.25 by control mice compared to 1.36 g ± 0.21 by CTαIKO mice 
between 48 and 72 h after initiation of the HFD, P=0.0009). 
The CTαIKO mice fed a HFD for 50 days gained 20% less body weight and had 40% less 
visceral fat mass compared to controls (Fig. 2D and 2E). The lower food intake observed in 
CTαIKO mice compared to control mice in the first week following initiation of the HFD appeared 
to be an acute response to the diet, as food intake was similar between CTαIKO mice and control 
mice by week 6 following HFD initiation (2.257± 0.16 g/day for control mice compared to 2.034 
± 0.17 g/day for CTαIKO mice, P=0.36). Nevertheless, fasting blood glucose was significantly 
lower in CTαIKO mice (Fig. 2F). In contrast to liver-specific CTα knockout mice (4), fasting 











plasma TG and cholesterol concentrations were not reduced in CTαIKO mice after being fed a 
HFD for 6 days or 50 days (Fig. 2G and 2H). Taken together, these data show that HFD feeding 
induces weight loss, while chronic feeding reduces weight gain in CTαIKO mice.     
Loss of intestinal CTα reduces chylomicron lipidation during HFD feeding 
To determine whether impaired dietary lipid absorption contributed to the acute weight 
loss in CTαIKO mice fed the HFD, we assessed postprandial plasma lipid concentrations. Control 
and CTαIKO mice were fasted overnight on day 3 following initiation of the HFD (prior to onset 
of severe weight loss) before re-feeding them for 2 h. Food intake was similar between CTαIKO 
mice and control mice during HFD re-feeding (not shown). Plasma TG concentrations were 60% 
lower and plasma non-esterified fatty acid concentrations were 30% lower in CTαIKO mice 
compared to controls after 2 h HFD re-feeding (Fig. 3A). Furthermore, CTαIKO mice had 
markedly less TG in the largest lipoprotein fraction compared to controls (Fig. 3B). Interestingly, 
despite a dramatic difference in plasma TG concentrations between genotypes after re-feeding, 
plasma ApoB concentrations were not different (Fig. 3C). This finding strongly suggests that 
lipidation of the intestine-derived lipoprotein particles was impaired in CTαIKO mice, whereas the 
number of particles secreted was not reduced. Total plasma cholesterol concentrations were 
similar between CTαIKO mice and control mice after HFD re-feeding (Fig. 3A). However, 
CTαIKO mice had less cholesterol in the largest lipoprotein fraction, while high-density 
lipoprotein (HDL) cholesterol (Fig. 3D) and plasma ApoA1 concentrations were not different 
between genotypes (Fig. 3C). To determine whether enhanced particle clearance contributed to 
the low postprandial plasma TG in CTαIKO mice, we challenged the mice with an intra-gastric 
bolus of olive oil after intra-peritoneal injection of Poloxamer-407, an inhibitor of lipoprotein 
lipase. Intestinal TG secretion remained blunted in CTαIKO mice over the 4 h study period (Fig. 











3E). Lower plasma TG after re-feeding was also observed in CTαIKO mice compared to controls 
fed a HFD for 6 weeks (1.14 ± 0.06 mmol/L in control mice compared to 0.83± 0.09 mmol/L in 
CTαIKO mice, P=0.03). Taken together, these data show that the intestine secretes TG-poor 
ApoB-containing particles in the absence of de novo PC synthesis.  
Loss of intestinal CTα impairs fatty acid uptake from the intestinal lumen into enterocytes 
We hypothesized that impaired intestinal TG secretion in CTαIKO mice was due to TG 
accumulation in enterocytes. However, CTαIKO mice had significantly lower jejunal TG 
concentrations than control mice after fasting and re-feeding (Fig. 4A and 4B). To track the 
spatial distribution of fatty acid uptake in the small intestine, we gavaged mice with [3H]-labeled 
triolein. The radioactivity in the mid-intestine of CTαIKO mice, where fatty acid absorption is 
typically highest, was strikingly lower than in control mice (Fig. 4C). As expected based on 
previous results, appearance of [3H]-label in plasma was significantly blunted in CTαIKO mice 
(Fig. 4D). Taken together, these data indicate that loss of intestinal CTα impairs fatty acid uptake 
from the intestinal lumen into enterocytes in the setting of a HFD.  
Histological examination of jejunal sections 2 h after a bolus of olive oil revealed fewer 
lipid droplets in enterocytes of CTαIKO mice compared to control mice fed the HFD (Fig. 4E).  
We also detected markedly fewer fluorescent lipid droplets in enterocytes of CTαIKO mice 
gavaged with Bodipy-labeled fatty acids (Fig. 4F). Moreover, electron microscopy showed a 
general absence of cytosolic lipid droplets in HFD-fed CTαIKO enterocytes 2 h after an oil 
challenge (Fig. 4G). Consistent with lower fatty acid concentrations in enterocytes, the mRNA 
levels of monoacylglycerol O-acyltransferase 2 (Mogat2), diacylglycerol O-acyltransferase 2 
(Dgat2) and lipid droplet-associated abhydrolase domain containing 5 (Abhd5) and cell death-
inducing DFFA-like effector c (Cidec) were significantly lower in CTαIKO intestines 2 h after a 











meal (Fig. 4H). These data suggest that impairment of intestinal PC synthesis reduces fatty acid 
uptake from the intestinal lumen and thereby limits fatty acid supply for lipid droplet and 
chylomicron formation. In further support of impaired fat absorption, non-esterified fatty acids 
were elevated in feces of CTαIKO mice compared to control mice (Fig. 4I).  
Loss of intestinal CTα impairs intestinal cholesterol absorption 
Cholesterol concentrations were also significantly higher in feces of CTαIKO mice 
compared to control mice (Fig. 5A). To examine cholesterol turnover, control and CTαIKO mice 
were administered with an oral gavage of [3H]-cholesterol and an intravenous injection of [14C]-
cholesterol, and the labels were measured in plasma and feces over 72 h. After 24 h, the 
appearance of [3H]-cholesterol in the circulation of CTαIKO mice was significantly lower than in 
control mice (Fig. 5B). Furthermore, cumulative fecal excretion of [3H]-neutral sterols over 72 h 
was higher in CTαIKO mice (Fig. 5C). These data suggest that luminal cholesterol absorption is 
impaired with loss of intestinal CTα. The rate of disappearance of radiolabel from plasma after 
intravenous injection of [14C]-cholesterol and cumulative [14C] accumulation in fecal neutral 
sterols was not different between genotypes (Fig. 5D and 5E), suggesting that hepatic cholesterol 
uptake was unaltered by loss of intestinal CTα. Furthermore, there was no difference in 
appearance of [3H] or [14C] in fecal bile salts between genotypes, suggesting that hepatic bile 
acid synthesis was not changed in response to reduced intestinal cholesterol absorption in 
CTαIKO mice (Fig. 5F and 5G). Despite impaired cholesterol absorption, jejunal cholesterol and 
cholesterol ester concentrations were unchanged in CTαIKO mice relative to controls (Fig. 5H and 
5I). Accordingly, mRNA abundance of several genes linked to cholesterol biosynthesis, 
including mevalonate kinase (Mvk), farnesyl diphosphate synthase (Fdps), cytochrome P450, 
family 51 (Cyp51) and NAD(P) dependent steroid dehydrogenase-like (Nsdhl), were induced in 











the jejunum of CTαIKO mice relative to controls (Fig. 5J). Induction of intestinal cholesterol 
biosynthesis in CTαIKO mice might be a compensatory response to impaired cholesterol 
absorption, or it might be due to altered intestinal phospholipid homeostasis in epithelial cells, as 
has recently been described (20) .  
Impaired lipid absorption in CTαIKO mice is linked to reduced expression of plasma 
membrane lipid transporters 
Microvillus length and structure were comparable between genotypes, suggesting that 
lipid malabsorption in CTαIKO mice is not due to structural damage to the intestinal epithelium 
(Fig. 6A). Intestinal Lpcat3 deletion in mice reduces passive lipid diffusion into enterocytes by 
reducing the incorporation of polyunsaturated fatty acids into intestinal PC  (9, 10). The mRNA 
levels of Lpcat3 were not altered in CTαIKO mice relative to controls (Fig. 6B). As expected, 
jejunal PC concentrations were significantly lower in CTαIKO mice re-fed the HFD, while PE 
concentrations were unchanged compared to controls (Fig. 6C and Fig 6D). However, the 
relative abundance of PC molecular species as measured by mass spectrometry was only 
minimally different between genotypes, with small increases in the relative abundance of PC 
(36:2) and PC (38:3) observed in CTαIKO mice (Fig. 6E). To validate our mass spectrometry 
results we performed gas-liquid chromatography analysis of the acyl chain constituents of PC 
and confirmed that the composition of fatty acids acylated to PC in the proximal intestine was 
comparable between genotypes (Fig. 6F). Therefore, impaired lipid absorption in CTαIKO mice is 
not due to changes in the relative abundance of PC molecular species as observed in mice 
deficient in intestinal Lpcat3. However, altered PC/PE ratio of intestinal membranes may impair 
passive lipid diffusion into enterocytes of CTαIKO mice.    











The membrane lipid transporters Cluster-determinant 36 (Cd36), Solute Carrier Family 
27 Member 4 (Slc27a4; Fatty acid transport protein 4) and NPC1 like intracellular cholesterol 
transporter 1 (Npc1l1) promote lipid absorption in intestinal epithelial cells (21-23). The mRNA 
levels of jejunal Cd36 were dramatically lower in CTαIKO mice relative to control mice (Fig. 6F). 
Furthermore, Slc27a4 and Npc1l1 mRNA levels were modestly lower in CTαIKO mice (Fig. 5F). 
Therefore, reduced expression of membrane transporters involved in intestinal lipid uptake 
relative to controls may at least partially account for impaired lipid absorption in CTαIKO mice. 
 
Loss of intestinal CTα enhances postprandial enteroendocrine hormone secretion  
Dietary fatty acids in the lumen of the distal intestine stimulate secretion of 
enteroendocrine hormones including glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) 
from L cells to control food intake and satiety (24). Since CTαIKO mice have impaired fatty acid 
absorption in the proximal small intestine resulting in increased fatty acid content of feces, we 
hypothesized that the higher abundance of fatty acids in the distal small intestine of CTαIKO mice 
would trigger GLP-1 and PYY secretion. CTαIKO mice had strikingly elevated active GLP-1 (~9-
fold) and PYY (~9-fold) in plasma 2 h after re-feeding the HFD (Fig. 7A and 7B). A major 
physiological function of GLP-1 is to promote insulin secretion from the pancreas (24). 
Accordingly, CTαIKO mice had a strong trend towards higher postprandial plasma insulin 
concentrations compared to controls (Fig. 7C). Fibroblast-like growth factor 21 (FGF21) is a 
hepatokine with multiple systemic effects on carbohydrate and lipid metabolism and is highly 
responsive to changes in nutrient intake (25-27). Circulating concentrations of FGF21 were 4.5-
fold higher in CTαIKO mice compared to controls after HFD re-feeding (Fig. 7D).  To test 
whether the observed changes to circulating hormone concentrations altered postprandial glucose 











metabolism, we re-fed mice a HFD for 2 h before administering them with an oral glucose 
challenge. CTαIKO mice had significantly lower peak blood glucose concentrations compared to 
controls after the glucose challenge (Fig. 7E). Importantly, re-fed plasma TG and GLP-1 were 
not different between tamoxifen-treated floxed controls and mice with a heterozygous deletion of 
intestinal CTα (Supplementary Fig.S1N and S1O). These data link impaired lipid uptake in the 
absence of intestinal CTα to enhanced postprandial enteric and hepatic hormone secretion, likely 
contributing to reduced body weight in CTαIKO mice relative to control mice.  
Loss of intestinal CTα alters enterohepatic circulation of bile acids and increases biliary PC 
secretion into the intestinal lumen  
We were initially surprised that CTαIKO mice can maintain epithelial cell turnover and 
intestinal viability in the absence of de novo PC synthesis. Thus, we hypothesized that increased 
biliary PC secretion may contribute to the maintenance of intestinal PC concentrations and 
intestinal epithelial cell viability in CTαIKO mice. To examine biliary lipid and bile acid secretion, 
we cannulated the gallbladders of mice fed the HFD. The rate of bile flow in CTαIKO mice was 
strikingly higher (~25%) than in control mice (Fig. 8A), coinciding with a doubling of biliary 
bile acid secretion, a 1.5-fold increase in phospholipid secretion and a 1.3-fold increase in 
cholesterol secretion (Fig. 8B-8D). Consistent with increased biliary lyso-PC delivery to the 
intestinal epithelium, the mRNA levels of jejunal Lpcat4, which catalyzes the addition of oleic 
acid to lyso-PC (28), was significantly higher in CTαIKO mice 2 h after HFD re-feeding (Fig. 8E). 
Therefore, a higher rate of delivery of biliary PC to the intestines of CTαIKO mice may contribute 
to their capacity to maintain intestinal epithelial cell viability in the absence of de novo intestinal 
PC synthesis.  











While total biliary bile acid concentrations were higher in CTαIKO mice, the bile acid 
species composition was largely unaltered, except for taurodeoxycholic acid, which was reduced 
(Fig. 8F). Consequently, the bile acid hydrophobicity index was similar between control and 
CTαIKO mice (Fig. 8G).  Additionally, a non-significant trend towards higher plasma bile acid 
concentrations in CTαIKO mice fed the HFD was observed (Fig. 8H). There was no change in the 
hepatic expression of genes involved in bile acid synthesis, and total fecal bile acid 
concentrations were not different between CTαIKO mice and control mice fed the HFD (Fig. 8I 
and 8J). These data strongly indicate that enhanced biliary bile acid and lipid secretion in CTαIKO 
mice is not driven by an increase in hepatic bile acid synthesis.  
There was a robust increase in mRNA levels of the apical sodium-bile acid transporter, 
solute carrier family 10 member 2 (Slc10a2/Asbt; mainly restricted to the ileum under normal 
conditions), in the jejunum of CTαIKO mice (Fig. 8K). An increase in jejunal Asbt is predicted to 
increase bile acid absorption in the proximal small intestine and to accelerate enterohepatic 
cycling of bile acids (29). In line with increased Asbt-mediated bile acid uptake in the proximal 
small intestine, mRNA levels of the bile-acid transporter Fabp6 had a strong tendency towards 
an in increase the jejunum of CTαIKO mice compared to controls 2 h after re-feeding. 
Furthermore, ileal Slc10a2, Fabp6 and Slc51b mRNA levels were not different, while ileal 
Slc51a were lower in CTαIKO mice than in ileums from control mice. Thus, loss of intestinal CTα 
stimulates the secretion of bile acids and lipids from the liver by a mechanism that involves a 
















In this study we show that intestinal PC synthesis via CTα plays a crucial role in 
coordinating the metabolic response of mice to HFD feeding. Our data suggest that the metabolic 
response to a HFD in CTαIKO mice is driven by a combination of impaired dietary lipid 
absorption, increased secretion of the fat-induced satiety hormones GLP-1 and PYY, and 
reduced food intake. Furthermore, a shift in expression of bile-acid responsive genes to the 
proximal small intestine of CTαIKO mice is linked to accelerated enterohepatic bile acid cycling. 
Loss of intestinal CTα is not well tolerated by some mice fed a HFD, indicating that de novo PC 
synthesis is specifically required for normal intestinal metabolic function. Furthermore, our data 
show that re-acylation of lyso-PC from the intestinal lumen cannot compensate for loss of CTα-
derived PC in enterocytes.  
Mice with intestinal deletion of the gene encoding the PC remodeling enzyme Lpcat3 
have reduced chylomicron secretion when fed a chow diet due to failure to incorporate 
polyunsaturated fatty acids into intestinal PC, which alters membrane dynamics and fatty acid 
uptake (9, 10). In contrast, we found that de novo PC synthesis is not required for chylomicron 
secretion in the setting of a low-fat diet. This observation suggests that the re-acylation of lyso-
PC derived from bile can fully accommodate chylomicron assembly under these conditions. 
However, an increase in cellular fatty acid concentrations increases cellular demand for PC to 
maintain membrane lipid homeostasis and produce the surface monolayer for lipid droplets and 
lipoproteins (2). Accordingly, HFD-fed CTαIKO mice have disrupted intestinal metabolic 
function (likely due to constant influx of fatty acids into intestinal epithelial cells which increases 
cellular PC demands) including impaired dietary lipid uptake (despite minimal changes to the 
relative abundance of polyunsaturated PC species or Lpcat3 expression in the intestine). 











Therefore, both pathways for intestinal PC formation (i.e. de novo PC synthesis and PC 
remodeling) are independently required for dietary lipid absorption when consuming a HFD. 
Furthermore, Lpcat3-deficient mice do not experience changes in bile acid concentrations (10), 
suggesting that the pathways of de novo PC synthesis and PC remodeling also control distinct 
aspects of enterohepatic physiology.   
We used a radiolabeled tracer to demonstrate that CTαIKO mice fed a HFD have impaired 
jejunal fatty acid uptake, resulting in the production of chylomicrons with lower TG content. 
Impaired lipid uptake in mice lacking intestinal de novo PC synthesis is not due to gross damage 
to the intestinal epithelium, as electron microscopy revealed an intact brush border membrane. 
Instead, loss of intestinal CTα is linked to intestinal metabolic dysfunction in the setting of a 
HFD including reduced expression of genes involved in dietary lipid absorption. Targeted 
deletion of Mogat2 (13), Cd36 (21), Abhd5 (30) and Npc1l1 (23), all of which are lower in the 
intestines of CTαIKO mice relative to controls, impairs dietary lipid absorption. Therefore, 
intestinal de novo PC synthesis apparently maintains a network of genes involved in dietary lipid 
uptake.  
The intestinal epithelium is highly active in cell division, growth, differentiation, and 
secretion i.e. processes that require adequate PC supply (2). Therefore, we were surprised that 
CTαIKO mice can maintain epithelial cell turnover and intestinal viability in the absence of de 
novo intestinal PC synthesis. Nevertheless, increased biliary PC secretion may contribute to the 
maintenance of intestinal PC concentrations in CTαIKO mice. We unexpectedly found that 
deletion of intestinal CTα doubles the rate of biliary bile acid secretion in CTαIKO mice compared 
to control mice. Because bile acids drive bile flow as well as biliary cholesterol and phospholipid 
secretion, these parameters were also significantly higher in CTαIKO mice (31). The higher rate of 











delivery of bile acids (with similar composition to bile acids in controls) into the intestinal lumen 
of CTαIKO mice implies that impaired fatty acid absorption with loss of intestinal CTα is not due 
to a deficiency of mixed micelles required for efficient fat absorption. Furthermore, since the 
cholesterol labeling study, the analysis of fecal bile output, and measurement of expression of 
bile acid-synthetic genes revealed that hepatic bile acid synthesis is not induced by loss of 
intestinal CTα, enterohepatic cycling of bile acids is likely accelerated. This hypothesis is 
supported by a shift in expression of Slc10a2 and Fabp6 towards more proximal parts of the 
small intestine. A shift in the expression of bile-acid responsive genes to the proximal intestine 
has been reported previously in mice lacking intestinal GATA4, a transcription factor that 
controls jejunal-ileal identity (32, 33). The change in spatial expression of bile-acid responsive 
genes in intestinal GATA4 deficient mice is also linked to impaired lipid absorption (33) and 
increased bile flow (29). Clearly, the molecular mechanisms that regulate crosstalk between the 
intestine and liver in controlling bile formation in CTαIKO mice require further research. Changes 
to enterohepatic circulation of bile acids can influence lipid, carbohydrate, and energy 
metabolism (34). Furthermore, bile acids increase the circulating level of FGF21 (35), a 
hepatokine that is increased in CTαIKO mice and that reduces adiposity when administered 
pharmacologically (25). Therefore, changes in bile acid metabolism may contribute to metabolic 
adaptations in the CTαIKO mice fed a HFD. 
GLP-1 and PYY are hormones that can influence energy balance through both the enteric 
nervous system and peripheral targets after nutrient-induced secretion from L cells (24). Under 
normal conditions, most dietary fatty acids are absorbed in the proximal small intestine (Fig. 
4C). However, if high concentrations of fatty acids reach L cells of the distal intestine they can 
enhance GLP-1 and PYY secretion (24). Accordingly, mice with intestinal deletion of genes 











involved in dietary fat absorption, including Mogat2 (13), Dgat1 (36) and Lpcat3 (10), have 
relatively high postprandial plasma GLP-1 concentrations. Similarly, impaired HFD absorption 
in the proximal small intestine of CTαIKO mice allows fatty acids to reach the distal intestine to 
potentiate enteroendocrine hormone secretion. The stimulation of GLP-1 and PYY secretion by 
fatty acids in CTαIKO mice likely contributes to their relatively more severe response to a HFD 
compared to a chow diet, as was observed in intestine-specific Lpcat3-deficient mice (10). High 
postprandial plasma GLP-1 is associated with increased insulin secretion and lower blood 
glucose concentrations in CTαIKO mice compared to control mice fed a HFD. Furthermore, 
enhanced GLP-1-mediated insulin secretion might account for the lower plasma free fatty acid 
concentrations in CTαIKO mice compared to controls by suppressing lipolysis in adipocytes. 
Additionally, enhanced PYY secretion in CTαIKO mice could contribute to their reduced body 
weight by interacting with brain regions that control energy balance (37). Taken together, our 
findings demonstrate that modulation of intestinal phospholipid metabolism can influence whole-
body physiology by enhancing the secretion of metabolically active hormones.  
In conclusion, this study demonstrates that intestinal de novo PC synthesis plays a central 
role in dietary lipid absorption during HFD feeding. Loss of intestinal CTα amplifies 
postprandial GLP-1 and PYY secretion and alters circulating glucose and free fatty acid 
concentrations, linking gut phospholipid synthesis to whole-body nutrient disposal and 
metabolism. Our studies also reveal an unexpected role for intestinal de novo PC synthesis in the 
maintenance of normal enterohepatic circulation of bile acids, potentially by governing the 
spatial expression of the bile-acid transporter Slc10a2 in the intestine. Therefore, a 
physiologically normal response to dietary fat intake depends on de novo PC synthesis in the 











intestinal epithelium, and the re-acylation of PC derived from extra-intestinal sources cannot 
fulfill this requirement.  
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Fig.1. Intestinal PC concentrations are reduced in CTαIKO mice fed a chow diet, but fat absorption 
capacity is unaltered. (A) Pcyt1a mRNA abundance, and (B) CTα enzyme activity in the jejunum and 
ileum of control and CTαIKO mice 5 days after Cre induction. Male control and CTαIKO mice were fed 
a chow diet for 6 weeks following Cre induction before being fasted for 10h, intraperitoneal injected with 
Poloxamer-407, and gavaged with olive oil. (C) Fasting body mass of male control mice and CTαIKO
mice fed the chow diet for 6 weeks (n=10-11/group). (D) Representative H&E stained jejunum sections 
from control mice and CTαIKO mice fed the chow diet for 6 weeks. (E) PC concentrations in the jejunum 
and ileum (n=5/group). (F) PE concentrations in the jejunum and ileum (n=5/group). (G) Molar ratio of 
PC-to-PE in the jejunum and ileum (n=5/group). (H) Fasting plasma cholesterol, (I) fasting plasma TG, 
and (J) Plasma TG before and 1, 2, 3, 4 h following the oral bolus of  olive oil in mice fed the chow diet 
for 6 weeks. Values are means ± SEM, n=5/group.*p<.05, **p<.01, ***p<.001, ****p<.0001.
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Fig.2. HFD feeding initially induces rapid weight loss, while chronic HFD feeding reduces 
weight gain, in CTαIKO mice. (A) Body mass change relative to total body mass at time of 
initiation of the HFD; graph is representative of 2 independent experiments 
(n=12 control and 14 CTαIKO mice). (B) Visceral fat mass, (C) plasma leptin concentrations, 
and (D) liver TG of control and  CTαIKO mice on day 6 following initiation of the HFD (n=6/group).
(D) Body mass of control mice and CTα IKO mice on day 0 and day 50 after initiation of the 
HFD (n=5/group). (E) Visceral fat mass, and (F) blood glucose concentrations of control mice 
and CTαIKO mice on day 50 after initiation of the HFD (n=5/group). (G) Fasting plasma TG, 
and (H) fasting plasma cholesterol concentrations of control mice and CTα IKOmice on 
day 6 and day 50 after initiation of the HFD (n≥5/group). All mice were female.
 Values are means ± SEM. *p<.05, ****p<.0001.
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Fig. 3. CTαIKO mice fed a HFD have impaired intestinal TG secretion after a meal. Control and CTαIKO
mice were fasted overnight and re -fed the HFD for 2 h. (A) Plasma TG, non-esterified fatty acids, and 
cholesterol after re-feeding (n=10/group). (B) FPLC of plasma lipoprotein TG after re -feeding (pooled 
plasma samples from n=5/group). ( C) Representative immunoblot of plasma apolipoproteins after 
re -feeding (ApoB and ApoA1 were run on separate gels). (D) FPLC of plasma lipoprotein cholesterol after 
re-feeding (pooled plasma samples from n=5/group). (E) Plasma TG before and 1, 2, 3, 4 h following an 
oral bolus of olive oil and intraperitoneal injection of Poloxamer-407. (n=4/group). All mice were female. 
Values are means ± SEM. *p<.05, ****p<.0001.
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Fig.4. CTαIKO mice fed a HFD have impaired passage of fatty acids from the intestinal lumen 
into enterocytes. Jejunal TG concentrations of female control and CTαIKO mice after (A) fasting or
(B) 2h after re-feeding the HFD (n=5-6/group). Male control and C TαIKO mice were fasted for 4 h
on day 3 following initiation of the HFD before receiving an oral bolus of 5µCi [ 3H]-labeled 
triolein in 150µL olive oil for 2h (n=5/group). (C) Radiolabel in intestine segments 2 h after 
[3H]-labeled triolein gavage. (D) Plasma radiolabel before and 30, 60, 90 and 120 mins after a 
[3H]-labeled triolein gavage. Female control and CTαIKO mice were fasted for 4 h on day 3 
following initiation of the HFD before receiving an oral bolus of Bodipy-labelled olive oil. (E) 
Representative H&E stained proximal intestine sections of control and CTαIKO mice 2 h after oil
gavage. (F) Fluorescence microscope images of jejunal sections 2 h after Bodipy-labeled oil 
gavage. (G) Representative Transmission Electron Micrographs of jejunal enterocytes 2 h after 
oil gavage. (H) Jejunal mRNA abundance of genes involved in chylomicron and lipid droplet 
formation (n=≥5/group). (I) Fatty acids in fecal samples from female control and CTαIKO mice 
















Fig. 5. Loss of intestinal CTα reduces dietary cholesterol absorption. (A) Cholesterol in fecal samples 
from female control and CTαIKO mice (n=5/group). Male control and CTαIKO received an oral dose of 
[3H]-cholesterol (2 µCi) with 6mg unlabeled cholesterol in 150µL of olive oil, and an intravenous 
injection of [14C]-cholesterol (1µCi) mixed in Intralipid®. Blood and feces were collected at 24, 48 and 
72 h after cholesterol administration (n=4/group). (B) Plasma [3H]-label at 24, 48 and 72 h. (C) 
Cumulative counts in fecal [ 3H]-labelled neutral sterols over 72 h.(D) Plasma [14C]-label at 24, 48 and 72 h 
(E) Cumulative counts in fecal [ 14C]-labelled neutral sterols over 72 h. (F) Cumulative [3H]-label in 
bile salts, and (G) cumulative [ 14C]-label in bile saltsover 72 h. (H) non-esterified cholesterol, (I) 
cholesterol esters, and (J) mRNA abundance of cholesterol synthetic genes in the jejunum of control























Fig.6. CTαIKO mice do not have damage to the brush border membrane or changes to 
relative abundance of jejunal PC molecular species but do have reduced jejunal expression of
 genes encoding proteins involved in lipid uptake. (A) Representative Transmission 
 Electron Micrographs of intestinal microvilli of control and CTαIKO mice fed the HFD.
 (B) Lpcat3 mRNA abundance in the jejunum of control and CTαIKO mice (n=5/group).
 (C) PC concentrations in the jejunum of control and CTαIKO mice 2 h after HFD
  re-feeding (n=5/group). (D) The relative bundance of jejunal PC molecular species,
 and (E) fatty acid methyl esters in PC of control mice and CTαIKO mice re-fed the HFD 
for 2 h (n=4-5/group) (F) mRNA abundance of Cd36, Slc27a4 and Npc1l1 in the jejunum 
 of control and CTαIKO mice 2 h after HFD re-feeding (n≥4/group). All mice were female.  
 Values are means ± SEM. *p<.05, **p< .01
.












Fig. 7. CTαIKO mice have enhanced GLP-1, PYY and FGF21 secretion after a high-fat meal. Control and 
CTαIKO mice were fasted overnight on day 3 following  initiation of the HFD before being re-fed for 2 h.
(A) Plasma active GLP -1 (n=5/group). (B) Plasma PYY (n=10/group). (C) Plasma insulin (n=10/group).
(D) Plasma FGF21 (n=10/group). (E) Blood glucose concentrations in control and CT αIKO mice re-fed the 
HFD for 2 h followed byan oral bolus of glucose. All mice were female. Values are means ± SEM. 
**p<.01, ***p< .001, ****p<.0001.
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Fig. 8. Loss of intestinal CTα enhances biliary bile acid secretion. Gallbladders of male control and 
CTαIKO mice were cannulated and bile was collected in pre-weighed containers (n=6-8/group). (A) Bile 
flow. (B) Bile salt secretion. (C) Phospholipid secretion. (D) Cholesterol secretion. (E) Jejunal Lpcat4 
expression. (F) Relative biliary bile acid composition. (G) bile acid hydrophobicity index. (H) Plasma bile 
acids. (I) mRNA abundance of hepatic genes involved in bile acid synthesis. (J) Fecal bile acids. (K) 
mRNA abundance of jejunal bile-acid responsive genes (n≥4/group), and (L) mRNA abundance of ileal 
bile-acid responsive genes in control mice and CTαIKO mice 2 h after re-feeding the HFD (n=3/group). 
Values are means ± SEM. *p<.05, **p<.01, ***p<.001, ****p<.0001.  
 
 by guest, on August 7, 2018
w
w
w
.jlr.org
D
ow
nloaded from
 
